The system enabled the in vitro study of both the phenotypical cellular changes induced by such FLT3 mutations and the different levels of response to anti-AML drugs, including the potential for discovering new therapeutic targets for AML treatments. The gene discussed is FLT3; the disease is acute myeloid leukemia.